Loss-of-Function of HtrA1 Abrogates All-TransRetinoic Acid-Induced Osteogenic Differentiation of Mouse Adipose-Derived Stromal Cells Through Deficiencies in p70S6K Activation by Glanz, Stephan et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Loss-of-Function of HtrA1 Abrogates All-TransRetinoic Acid-Induced
Osteogenic Differentiation of Mouse Adipose-Derived Stromal Cells Through
Deficiencies in p70S6K Activation
Glanz, Stephan; Mirsaidi, Ali; López-Fagundo, Cristina; Filliat, Gladys; Tiaden, André N; Richards,
Peter J
Abstract: Unspecified
DOI: 10.1089/scd.2015.0368
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-127468
Accepted Version
Originally published at:
Glanz, Stephan; Mirsaidi, Ali; López-Fagundo, Cristina; Filliat, Gladys; Tiaden, André N; Richards,
Peter J (2016). Loss-of-Function of HtrA1 Abrogates All-TransRetinoic Acid-Induced Osteogenic Dif-
ferentiation of Mouse Adipose-Derived Stromal Cells Through Deficiencies in p70S6K Activation. Stem
Cells and Development, 25(9):687-698. DOI: 10.1089/scd.2015.0368
For Peer Review Only/Not for Distribution
 1 
Loss-of-Function of HtrA1 Abrogates All-Trans Retinoic Acid-Induced Osteogenic 
Differentiation of Mouse Adipose-Derived Stromal Cells Through Deficiencies in p70S6K 
Activation 
 
Stephan Glanz
1,2*
, Ali Mirsaidi
1,*
, Cristina López-Fagundo
1
, Gladys Filliat
1,2
, André N. Tiaden
1
, 
Peter J. Richards
,1,2
 
 
1
Bone and Stem Cell Research Group, CABMM, University of Zurich, 8057 Zurich, 
Switzerland, 
2
Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, 
8057 Zurich, Switzerland. *Authors contributed equally. 
 
Author Email addresses: Stephan.glanz@cabmm.uzh.ch, ali.mirsaidi@cabmm.uzh.ch, 
clopezfagundo@gmail.com, gladys.filliat@cabmm.uzh.ch, nicki.tiaden@cabmm.uzh.ch,   
peter.richards@cabmm.uzh.ch 
 
Running title: Regulation of mASC Osteogenesis by HtrA1 
 
To whom correspondence should be addressed: Dr. Peter J. Richards, Center for Applied 
Biotechnology and Molecular Medicine, University of Zürich, Winterthurerstrasse 190, Zürich 
8057, Switzerland, Tel:+41-44-635-3800, Email: peter.richards@cabmm.uzh.ch 
 
 
 
Page 5 of 46
Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801
Stem Cells and Development
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only/Not for Distribution
 2 
Footnotes and Abbreviations 
The abbreviations used are: ALP, alkaline phosphatase; ATRA, all-trans retinoic acid; BMP, 
bone morphogenetic protein; BMPR, BMP receptor; GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase; 4E-BP1, eukaryotic initiation factor 4E binding protein 1; hBMSC, human bone 
marrow stromal cells; HtrA1, high temperature requirement protease A1; mASC, mouse adipose-
derived stromal cells; mBMSC, mouse bone marrow stromal cells; mTOR, mammalian target of 
rapamycin; p70S6K, p70 ribosomal protein S6 kinase; rpS6, ribosomal protein S6; SAM, 
senescence-accelerated mouse; TSC2, Tuberous sclerosis complex 2.  
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Abstract 
All-trans retinoic acid (ATRA) is a potent inducer of osteogenic differentiation in mouse 
adipose-derived stromal cells (mASCs), although the underlying mechanisms responsible for its 
mode of action have yet to be completely elucidated. High temperature requirement protease A1 
(HtrA1) is a newly recognized modulator of human multipotent stromal cell (MSC) osteogenesis 
and as such, may play a role in regulating ATRA-dependent osteogenic differentiation of 
mASCs. In the current study, we assessed the influence of small interfering RNA (siRNA)-
induced repression of HtrA1 production on mASC osteogenesis and examined its effects on 
ATRA-mediated mammalian target of rapamycin (mTOR) signaling. Inhibition of HtrA1 
production in osteogenic mASCs resulted in a significant reduction of alkaline phosphatase 
(ALP) activity and mineralized matrix formation. Western blot analyses revealed the rapid 
activation of Akt (Ser473) and p70S6K (Thr389) in ATRA-treated mASCs, and that levels of 
phosphorylated p70S6K were noticeably reduced in HtrA1-deficient mASCs. Further studies 
using mTOR inhibitor rapamycin and siRNA specific for the p70S6K gene Rps6kb1 confirmed 
ATRA-mediated mASC osteogenesis as being dependent on p70S6K activation. Finally, 
transfection of cells with a constitutively active rapamycin-resistant p70S6K mutant could 
restore the mineralizing capacity of HtrA1-deficient mASCs. These findings therefore lend 
further support for HtrA1 as a positive mediator of MSC osteogenesis and provide new insights 
into the molecular mode of action of ATRA in regulating mASC lineage commitment. 
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Introduction 
Efficient osteogenic induction of mouse adipose-derived stromal cells (mASCs) is reliant on the 
actions of all-trans retinoic acid (ATRA), the carboxylic acid form of vitamin A [1-7]. This is in 
contrast to mouse and human bone marrow stromal cells (BMSCs), where dexamethasone is 
primarily used to instigate osteogenesis through upregulation of four and a half LIM domains 2 
(FHL2) and activation of Wnt/β catenin signaling [8]. ATRA’s ability to influence osteoblast 
differentiation has been observed in several different cell systems and is considered to be largely 
dependent on the concentration of ATRA used. Whilst ATRA acts to enhance osteogenesis at 
micromolar concentrations [1-7, 9, 10], at nanomolar concentrations, it has been shown to inhibit 
both osteoblast gene expression and mineralization [11-13]. The concentration of ATRA used to 
stimulate mASC osteogenesis in vitro is generally within the range of 1 to 5 µM, where it acts to 
enhance the expression of several osteogenic markers including alkaline phosphatase (Alpl) and 
osteopontin (Spp1), and to induce mineralization of mASC-derived osteoblasts [3, 4]. In 
addition, ATRA’s ability to direct mASCs along the steoblast lineage in vitro has also been 
exploited for the purpose of enhancing mASC-induced new bone formation in vivo. Priming of 
mASCs with ATRA prior to their implantation into mouse calvarial defects resulted in 
accelerated bone regeneration as compared to mice treated with unstimulated mASCs [14]. 
However, the mechanisms through which ATRA instigates its osteogenic effects in these cells 
remain unclear. Findings from studies investigating the combined effects of ATRA and bone 
morphogenetic protein (BMP)-2 on mASC osteogenesis suggested that ATRA’s primary 
function was to regulate BMP signaling through enhanced BMP receptor (BMPR) expression 
[1]. However, ATRA also has the ability to induce osteogenic differentiation of mASCs in the 
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absence of exogenous BMP-2 [2-7]. Therefore, it’s likely that in addition to BMP signaling, 
ATRA targets other pathways critically involved in regulating mASC osteogenesis. 
We have previously identified high temperature requirement protease A1 (HtrA1) as a 
novel mediator of human BMSC (hBMSC) differentiation, where it acts to enhance osteogenesis 
and subsequent mineralization by differentiating bone-forming cells [7]. Furthermore, HtrA1 
expression is upregulated in mASCs in response to ATRA-containing osteogenic induction 
medium [7]. HtrA1 is a member of the HtrA family of serine proteases and has been linked to 
various biological processes by virtue of its ability to interact with numerous intracellular and 
extracellular substrates [15]. Tuberous sclerosis complex 2 (TSC2) was the first cytoplasmic 
HtrA1 substrate to be identified, and its degradation by HtrA1 was shown to result in activation 
of the mammalian target of rapamycin (mTOR) pathway as confirmed by alterations in the 
phosphorylation of downstream targets eukaryotic initiation factor 4E binding protein 1 (4E-
BP1) and p70 ribosomal protein S6 kinase (p70S6K) [16]. This bears particular significance with 
regards to mASC osteogenesis, based on the fact that mTOR signaling plays a positive role in the 
osteogenic induction of several cell types including BMSCs [17-19]. However, no studies have 
yet sort to investigate its involvement in mediating the osteoinductive effects of ATRA on 
mASCs, or whether HtrA1’s ability to influence mTOR signaling plays a role in determining 
mASC osteogenic potential. In the present study, we investigated the role of HtrA1 in the 
ATRA-dependent differentiation of mASCs into mineral-forming bone cells and assessed its 
influence over mTOR signaling events during the course of mASC osteogenesis. 
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Materials and Methods 
Materials 
Antibodies specific for non-phosphorylated Akt, mTOR, p70S6K, 4E-BP1 and rpS6; 
phosphorylated Akt (Ser473), mTOR (Ser2448), p70S6K (Thr389), 4E-BP1 (Thr37/46) and rpS6 
(Ser235/236) were all purchased from Cell Signaling, BioConcept (Allschwil, Switzerland). 
Mouse monoclonal anti-tubulin was from Sigma-Aldrich (Buchs, Switzerland). Mouse HA-
probe antibody and anti-GAPDH were from Santa Cruz Biotechnology, LabForce AG (Muttenz, 
Switzerland). A polyclonal anti-HtrA1 antibody was generated as previously described [20]. 
HRP-labeled secondary antibodies specific for mouse or rabbit IgG were purchased from 
Jackson ImmunoResearch (Suffolk, UK). Rapamycin was purchased from Enzo Life Science 
(Lausen, Switzerland). BMP-2 was kindly donated by Prof. Franz Weber (University of Zurich), 
and ATRA, dexamethasone and PF-4708671 were from Sigma-Aldrich. The expression plasmids 
pRK7-HA-S6K1-F5A-E389-R3A (Addgene plasmid # 8991) and pRK7-HA-S6K1-KR 
(Addgene plasmid # 8985), were kind gifts from John Blenis [21]. 
 
Isolation and Culture of mASCs 
Primary mASCs were isolated from SAM mice as previously described [4, 5]. All animal 
research procedures were approved by the Animal Experimentation Committee of the Veterinary 
Office of the Canton of Zurich, Switzerland and followed the guidelines of the Swiss Federal 
Veterinary Office for the use and care of laboratory animals. Briefly, subcutaneous inguinal fat 
pads were removed and digested in Hepes buffer containing 0.1% collagenase A (Roche 
Diagnostics, Rotkreuz, Switzerland) and 0.2% bovine serum albumin for 40 min at 37
o
C. 
Adherent stromal cells were maintained in complete medium consisting of Dulbecco’s modified 
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eagle medium (DMEM-low glucose, with GlutaMAX) (Life Technologies, Zug, Switzerland), 
supplemented with 10% fetal bovine serum (FBS) (Bioswisstec, Schaffhausen, Switzerland) and 
antibiotics. Supernatant was replaced after 1 day with fresh complete medium and cells were 
used between passage 1 and 4 following initial analysis for mesenchymal and hematopoietic cell 
markers by flow cytometry as previously described [4].  
 
Osteogenic Differentiation of mASCs 
mASCs were plated at 5000 cells/cm
2
 and incubated in alpha-minimum essential medium (α-
MEM) (Life Technologies), supplemented with 10% FBS (Bioswisstec), 50 µM L-ascorbic acid 
2-phosphate sesquimagnesium salt hydrate, 10 mM β-glycerophosphate and either 5 µM ATRA 
or 100 nM dexamethasone and 100 ng/ml BMP-2 for up to 21 days with regular changes of 
medium as previously described [4]. Where indicated, PF-4708671 was also added to mASCs 
undergoing osteogenic differentiation in order to assess the influence of S6K1 inhibition on 
ATRA-dependent osteogenic induction. Alkaline phosphatase (ALP) activity was quantified in 
cell lysates using p-nitrophenylphosphate (pNPP) liquid substrate (Sigma-Aldrich) and values 
normalized to total protein content and reaction time as previously described [4]. Mineralization 
was visualized using Alizarin red and the amount of staining determined by measuring optical 
densities at 570 nm following extraction using 10% cetylpyridinium chloride (Sigma-Aldrich). 
Optical densities were then converted to micromoles (µM) of Alizarin red using a standard curve 
and normalized to cell number. The mean cell number was determined by automated counting of 
4′,6-diamidino-2-phenylindole (DAPI) stained nuclei in at least 6 random fields of view. Images 
were captured on a Leica DMI 6000  inverted fluorescence microscope (Leica Microsystems, 
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Heerbrugg, Switzerland). Image processing and nuclear counts were performed using NIH 
ImageJ software.  
 
Quantitative Reverse Transcription PCR (RT-qPCR) 
Total RNA was isolated from mASCs and purified using TRIzol reagent (Invitrogen AG, Basel, 
Switzerland) according to the manufacturer’s instructions. RNA (0.5 µg) was reverse transcribed 
to cDNA using Superscript II (Invitrogen AG) and random hexanucleotide primers (Promega 
AG, Dübendorf, Switzerland). Quantification of mRNA expression was performed with TaqMan 
Gene Expression Assays (Applied Biosystems, Rotkreuz, Switzerland) specific for HtrA1 
(Mm00479887), Rps6kb1 (Mm01310033), Alpl (Mm01187117) and Spp1 (Mm01611440) using 
the StepOnePlus Real-Time PCR System (Applied Biosystems) and values normalized to 
Mrps12 (Mm00488728)  mRNA levels and presented as fold change according to the 2
-∆∆CT
 
method. Each 10 µl reaction consisted of 1x TaqMan Fast Universal PCR Master Mix (Applied 
Biosystems), 1x TaqMan Gene Expression Assay and 10 ng cDNA (based upon initial RNA 
concentrations). All reactions were performed in triplicate in fast optical 96-well reaction plates 
(Applied Biosystems) at 95
o
C for 20 seconds and 40 cycles of 95
o
C for 1 second and 60
o
C for 20 
seconds. 
 
Western Blot Analysis 
Total cellular protein was extracted from mASCs using CelLytic M (Sigma-Aldrich) containing 
protease and phosphatase inhibitor cocktails (Sigma-Aldrich). For the analysis of HtrA1 in 
mASC supernatants, cells were treated for 3 days with osteogenic induction medium and then for 
a further 24 h in fresh FCS-free osteogenic induction medium before harvesting and 
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concentrating supernatants 30-fold using Amicon Ultra-15, 10 kDa mwco filter units (Millipore). 
In each case, protein amounts were quantified using BioRad Protein Assay (BioRad, Reinach, 
Switzerland). Protein samples were boiled for 5 min in loading buffer (50 mM Tris-HCl, pH 6.8, 
2% SDS, 10% glycerol, 100 mM DTT, 0.002% Bromophenol blue) and equal amounts of protein 
loaded onto 12% SDS-PAGE gels. Protein was then electroblotted onto PVDF membranes using 
the Trans-Blot Turbo blotting system (BioRad) and incubated in 5% skimmed milk, 50 mM Tris-
HCl, pH 7.6, 150 mM NaCl, 0.1% Tween 20 (TBST) for 1 h at room temperature. Membranes 
were then incubated overnight at 4
o
C with primary antibodies specific for HtrA1 or 
phosphorylated or non-phosphorylated Akt, mTOR, p70S6K, rpS6 and 4E-BP1. Monoclonal 
mouse anti-tubulin or anti-GAPDH were used to control for equal protein loading of cell lysates. 
Coomassie blue staining was used to control for equal protein loading of cell supernatants. After 
washing in TBST three times for 5 min each, membranes were incubated with a HRP-conjugated 
anti-mouse or anti-rabbit IgG (1:10’000) for 1 h at room temperature. Following a further 
washing step, peroxidase activity was detected using SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific, Lausanne, Switzerland). Protein levels were quantified using NIH 
ImageJ software. Phosphorylated and non-phosphorylated protein values were first normalized to 
tubulin loading control and then the phosphorylation to total protein ratio calculated using the 
normalized values.  
 
Small Interfering RNA (siRNA) Studies 
Specific knock down of gene expression was performed with Silencer Select siRNA (Ambion, 
Life Technologies) specific for HtrA1 (s80180) or Rps6kb1 (s91055) using previously described 
methods [7]. Briefly, mASCs (1x10
5
 cells) were transfected with 20 nM of targeted siRNA or 
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negative control siRNA (Negative Control-1) using the NEON Transfection System (Life 
Technologies). Following transfection, cells were seeded in cell culture plates with fresh growth 
medium (without antibiotics) and incubated for 24 h at 37°C, 5% CO2. Medium was then 
replaced with either fresh growth medium or osteogenic differentiation medium and total RNA 
or protein harvested at selected time points for further analysis. The effects of siRNA mediated 
gene knockdown on osteogenic-induced mASC ALP activity and mineralization was determined 
using the ALP activity assay and Alizarin Red staining respectively.  
 
siRNA and Plasmid Co-Transfection 
mASCs were transfected with Silencer Select siRNA specific for HtrA1 or Negative Control-1 
and 1 µg of mammalian expression plasmid pRK7-HA-S6K1-F5A-E389-R3A (constitutively 
active p70S6K), pRK7-HA-S6K1-KR (kinase inactive p70S6K) or empty control plasmid 
pcDNA3 using the NEON Transfection System as described above. After 24 h, cells were 
induced to undergo osteogenesis and mineralization quantified after 21 days using Alizarin red 
staining as described above.  
 
Statistical Analysis 
Two-tailed unpaired Student’s t-test for comparison of two groups or one-way analysis of 
variance (ANOVA) with Tukey’s post-hoc test for multiple group comparisons were performed 
using SPSS19.0 (SPSS Inc., Chicago, IL). In all cases, a p-value of < 0.05 was considered 
statistically significant. 
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Results 
We have previously demonstrated that HtrA1 plays a vital role in the regulation of osteogenesis 
in hBMSCs [7]. In the current report, we further investigated this property of HtrA1 in ATRA-
stimulated mASCs and aimed to establish its role in regulating mASC osteogenesis and mASC-
derived osteoblast mineralization.   
 
HtrA1 Deficiency Impairs ATRA-Mediated mASC Osteogenic Differentiation 
In order to examine the influence of loss-of-function of HtrA1 on the osteogenic capacity of 
mASCs in response to treatment with osteogenic medium containing ATRA, we analyzed 
mineral production by mASC-derived osteoblasts, as well as ALP expression and enzyme 
activity. Analysis of HtrA1 in mASC supernatants by Western blot confirmed HtrA1 protein 
production to be effectively reduced in osteogenic mASCs treated with siRNAs specific for 
HtrA1 (Fig. 1A). We next assessed the influence of loss-of-function of HtrA1 on the osteogenic 
potential of mASCs. mASCs treated with control siRNA underwent efficient osteoblastogenesis 
and mineralization following stimulation with osteogenic medium for 10 days, as determined by 
Alizarin red staining (Fig. 1B). However, Alizarin red staining of osteogenic-induced mASCs in 
which HtrA1 had previously been depleted was noticeably reduced (Fig. 1B). Similarly, HtrA1 
deficiency also resulted in significant reductions in Alizarin red staining in mASCs induced to 
undergo osteogenic differentiation in response to BMP-2 treatment (supplementary Fig. S1). 
Further quantitative analysis of extracted Alizarin red stain revealed the mineralizing capabilities 
of HtrA1-deficient mASC-derived osteoblasts to be significantly impaired (p < 0.001) as 
compared to siControl (Fig. 1C). In accordance with our previous findings [7], ATRA-mediated 
osteogenic induction of mASCs resulted in significant increases in both HtrA1 (Fig. 1D) and Alpl 
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(Fig. 1E) expression levels in a time dependent manner. Similarly, ALP enzyme activity was also 
significantly enhanced in response to osteogenic induction at all time points tested (Fig. 1F). As 
expected, HtrA1 knockdown of mASCs significantly suppressed HtrA1 expression in osteogenic 
mASCs over the course of the study (Fig. 1D). ATRA-mediated increases in Alpl expression 
levels were also significantly impaired in HtrA1-deficient mASCs (Fig. 1E) and were 
accompanied by significant decreases in ALP enzymatic activity at all time points tested (Fig. 
1F). These findings therefore demonstrate a functional role for HtrA1 in regulating ATRA-
mediated mASC osteogenesis and in the generation of a mineralized matrix by mASC-derived 
osteoblasts. 
 
HtrA1 Deficiency Impairs ATRA-Mediated p70S6K Activation in mASCs 
Having demonstrated HtrA1 to be a necessary component for efficient mASC osteogenesis, we 
next considered its potential mode of action. Based on HtrA1’s previously reported role in the 
activation of mTOR targets p70S6K and 4E-BP1 in tumor cell lines [16], we assessed the 
possible influence of HtrA1 deficiency on mTOR signaling in ATRA-stimulated mASCs. As no 
studies have yet sought to determine the effects of ATRA-mediated osteogenic induction on 
mTOR signaling in mASCs, we initially performed a series of Western blot analyses to ascertain 
the activation status of kinases located both upstream and downstream of mTOR. 
Phosphorylation levels of Akt (Ser473), mTOR (Ser2448), p70S6K (Thr389) and 4E-BP1 
(Thr37/46) were assessed in mASCs over the course of 2 h following ATRA-mediated 
osteogenic induction. A noticeable increase in Akt and p70S6K phosphorylation was already 
evident in osteogenic-induced mASCs after only 10 min and had reduced to basal levels by 1 h 
(Fig. 2A). However, basal levels of phosphorylated mTOR were only minimally affected after 10 
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min, and 4E-BP1 remained relatively unchanged at all time points tested. We next proceeded to 
investigate the influence of HtrA1 silencing on Akt/mTOR/p70S6K/4E-BP1 phosphorylation in 
differentiating mASCs. Western blot analysis of cell lysates from HtrA1-deficient mASCs 
revealed no reduction in phospho-Akt levels, and only minor reductions in phospho-mTOR and –
4EBP1 levels as compared to siControl (Fig. 2B). By comparison however, HtrA1-deficient 
mASCs demonstrated marked reductions in the levels of phosphorylated p70S6K and rpS6. 
These results are therefore suggestive of ATRA-mediated p70S6K activation as being a potential 
HtrA1 target and a means by which it could influence ATRA-dependent mASC osteogenesis. 
 
Loss-of-Function of p70S6K Impairs mASC Osteogenesis 
In order to address the functional relevance of p70S6K activation in the context of mASC 
osteogenesis, we next assessed the effects of p70S6K inhibition on ALP expression and matrix 
mineralization in mASCs undergoing ATRA-mediated osteogenic differentiation. Short-term 
treatment of mASCs with the mTOR inhibitor rapamycin prior to osteogenic induction markedly 
reduced mTOR phosphorylation and completely abolished p70S6K phosphorylation, whilst Akt 
phosphorylation levels remained unaffected (Fig. 3A). Next, we evaluated the effects of long-
term exposure of mASCs to rapamycin with regards to their ability to differentiate into 
mineralizing osteoblasts. Alizarin red staining of osteogenic mASCs was significantly reduced 
by rapamycin treatment in a concentration dependent manner (Fig. 3B and C), thus confirming 
that mTOR signaling was required for mASC-derived osteoblastogenesis.  
Further investigations employing siRNA mediated knockdown of the p70S6K gene 
Rps6kb1 were also performed in order to assess the effects of specifically inhibiting p70S6K 
activity on mASC osteogenesis. p70S6K protein and activity levels were noticeably reduced in 
Page 17 of 46
Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801
Stem Cells and Development
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only/Not for Distribution
 14
Rps6kb1-deficient mASCs after short-term osteogenic induction (Fig. 4A). We next investigated 
the effects of Rps6kb1 knockdown on mASC-derived osteoblast mineralization using Alizarin 
red staining. A marked reduction in Alizarin red staining was observed in Rps6kb1-deficient 
mASCs after 14 days of culture in osteogenic medium (Fig. 4B). Further quantitative analysis of 
extracted Alizarin red stain revealed the mineralizing capabilities of p70S6K-deficient mASC-
derived osteoblasts to be significantly impaired as compared to siControl (p < 0.001) (Fig. 4C). 
In support of these findings, significant reductions in Alizarin red staining of mASC-derived 
osteoblasts were also observed in cultures treated with the specific S6K1 inhibitor PF-4708671 
(supplementary Fig. S2). Gene expression analyses of mASCs undergoing osteogenesis 
confirmed efficient Rps6kb1 knockdown throughout the course of the study and revealed a 
significant reduction in Rps6kb1 gene expression at day 14 in siControl in response to osteogenic 
induction (Fig. 4D). Furthermore, the expression levels of osteogenic markers Alpl (Fig. 4E) and 
osteopontin (Spp1) (Fig. 4F) in mASCs undergoing osteogenesis were significantly reduced in 
p70S6K-deficient cells. These results clearly identify p70S6K activation as being a necessary 
requirement for efficient osteogenic differentiation of mASCs and provide a potential means 
through which HtrA1 may regulate ATRA-mediated mASC osteogenesis. 
 
Restoration of HtrA1-Deficient mASC Osteogenesis Using a Constitutively Active p70S6K 
Mutant 
In view of the fact that mASC osteogenesis is dependent on both HtrA1 and p70S6K, and that 
loss-of-function of HtrA1 impairs p70S6K activation, we sought to determine whether 
transfection of mASCs with a constitutively active p70S6K mutant could relieve the detrimental 
effects of HtrA1 deficiencies on mASC osteogenesis. mASCs were transfected with either an 
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empty plasmid, or plasmids encoding a rapamycin-resistant constitutively active (p70S6KCA) or 
kinase inactive (p70S6KKI) HA-tagged p70S6K [21]. The results shown in Fig. 5A are 
representative of the controls used to confirm that the plasmids encoding p70S6KCA and 
p70S6KKI were performing as expected. Both protein products were labeled with an HA-tag, 
and so plasmid-mediated protein expression could be accurately and specifically detected using 
an anti-HA antibody. As shown in the top lane of Fig. 5A, HA-labeled protein is evident in cells 
treated with plasmids encoding p70S6KCA and p70S6KKI as expected, but no signal is detected 
in cells treated with empty plasmid as no HA-labeled protein has been produced. Cells 
transfected with empty plasmid therefore serve as an additional control to confirm Western blot 
specificity and the robustness of the cell transfection system used. The p70S6K substrate rpS6, is 
phosphorylated by activated p70S6K and therefore represents a useful means by which to 
visualize p70S6K activation by Western blot. As such, inhibition of p70S6K activity by 
rapamycin treatment is expected to result in reduced phosphorylated rpS6 (p-rpS6) levels. 
Indeed, upon rapamycin treatment of mASCs transfected with empty plasmid or plasmid 
encoding p70S6KKI, we observed a noticeable reduction in p-rpS6 levels in cells. This would be 
expected as neither the empty plasmid nor the kinase inactive p70S6KKI can generate active, 
rapamycin resistant p70S6K. However, cells expressing the rapamycin resistant, active 
P70S6KCA protein can still phosphorylate rpS6 even in the presence of rapamycin. Therefore, 
these results are confirmation that mASCs, when transfected with plasmid DNA, can produce the 
relevant p70S6K proteins and that they are either active (p70S6KCA) or inactive (p70S6KKI). 
RT-qPCR confirmed that siRNA mediated reduction of HtrA1 mRNA expression was unaffected 
in cells co-transfected with plasmid DNA (Fig. 5B). Next, we transfected HtrA1-deficient 
mASCs with empty plasmid, p70S6KCA or p70S6KKI and assessed their ability to influence 
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mASC-derived osteoblast formation through quantification of Alizarin red staining after 21 days. 
The assumption was that reduced p70S6K activity in HtrA1-deficient mASCs could be 
compensated for through expression of the constitutively active p70S6K (p70S6KCA), and 
thereby restore osteogenic potential. Indeed, as shown in Fig. 5C and 5D, Alizarin red staining 
was restored in HtrA1-deficient mASCs transfected with p70S6KCA. The kinase inactive (KI) 
p70S6K (p70S6KKI) was included to control as accurately as possible for the introduction of 
plasmid DNA into the cells and expression of p70S6K protein. It differs with respect to 
p70S6KCA in that it is not active, and so should not compensate for the reductions in p70S6K 
activity in HtrA1-deficient mASCs. This was indeed the case, as shown in Fig. 5C and 5D where 
Alizarin red staining could not be restored in HtrA1-deficient mASCs transfected with 
p70S6KKI. Empty plasmid was also included as an additional control, and demonstrated no 
influence over mASC osteogenesis as expected. Taken together, these findings identify p70S6K 
as being of critical importance in ATRA-mediated mASC osteogenesis and that activation of 
p70S6K is reliant, at least in part, on the actions of HtrA1.  
 
Discussion 
mASCs represent a readily available source of osteoprogenitor cells, which unlike mBMSCs, 
have the advantage of being able to sustain a high level of osteogenic differentiation potential 
with age and under conditions of low bone quality [4, 22-25]. Subsequently, mASCs are fast 
becoming the preferred choice for stem cell-based approaches in bone tissue engineering [26, 
27]. Certainly, results from our previous studies have confirmed that mASCs harvested from 
SAMP6 mice, a model for senile osteoporosis, have the capability of increasing bone quality 
when re-injected back into SAMP6 tibia [5]. However, despite their widespread usage, the 
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underlying mechanisms through which mASC osteogenic differentiation is controlled remains 
incompletely understood. In the current report, we identify the serine protease HtrA1 as being a 
positive regulator of ATRA-induced mASC osteogenesis and mASC-derived osteoblast 
mineralization. Furthermore, we provide evidence, which supports p70S6K as playing a role in 
mediating the pro-osteogenic effects of HtrA1 in mASCs in response to ATRA. 
 Mammalian HtrA1 was originally identified by Zumbrunn and Trueb [28] and has since 
been implicated in numerous biological processes and diseases [15, 29]. Findings from our own 
studies have revealed HtrA1 to be a potent modulator of hBMSC multipotency as evidenced by 
its ability to inhibit adipogenesis and stimulate osteogenesis [7]. However, several studies also 
exist in which HtrA1 has been classified as a negative regulator of osteogenesis both in vitro and 
in vivo [30, 31]. Clearly therefore, further investigations are required in order to clarify HtrA1’s 
function in osteogenesis and to ascertain its potential mechanism of action. Here we provide 
further evidence in support of HtrA1’s role as a positive regulator of MSC osteogenesis.  
HtrA1 is classified as a secreted serine protease and as such, its influence over cellular 
processes is largely thought to be due to its extracellular actions [7, 20, 32]. However, it is also 
equally likely that HtrA1 instigates many of its effects intracellularly. Indeed, HtrA1 has been 
shown to interact with and functionally regulate several intracellular substrates including tubulin 
[33], proTGFβ1 [34], tau [35], X-linked inhibitor of apoptosis protein (XIAP) [36] and TSC2 
[16]. In the context of the present study, HtrA1’s regulatory influence over TSC2 activity holds 
particular relevance given the importance of mTOR signaling in stem cell multipotency [17-19].  
The mTOR protein makes up the catalytic subunit of two separate complexes, namely 
mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) [37]. mTORC1 functions to 
control cell growth and protein synthesis through phosphorylation of 4E-BP1 and p70S6K, and 
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has been implicated in osteoblast differentiation [17, 38-40]. mTORC1 is negatively regulated by 
the GTPase-activating protein TSC1/2 complex and as such, relies on the actions of Akt for its 
activation through phosphorylation of TSC2 [41]. Although several studies have demonstrated 
activation of the Akt/mTOR signaling pathway in response to ATRA [42-44], no investigations 
have yet been undertaken to examine Akt/mTOR activation in ATRA-stimulated mASCs or to 
evaluate its consequences for their commitment towards osteoblasts. Our findings have 
demonstrated that the Akt/mTOR/p70S6K pathway is rapidly activated in mASCs in response to 
ATRA. Similar rapid increases in several other kinase cascades have previously been 
demonstrated in various cell systems in response to ATRA [45-48]. Such effects are considered 
to be independent of the classical genomic effects of ATRA, and are instead regulated through 
atypical, non-genomic events possibly through interactions with membrane-associated retinoic 
acid receptors (RARs) [49]. The ability of the mTOR inhibitor rapamycin to completely suppress 
ATRA-mediated p70S6K activation in these cells suggests that despite the minimal increases in 
phospho-mTOR (Ser2448), ATRA-mediated p70S6K activation in mASCs is rapamycin 
sensitive and as such, reliant on mTOR signaling. It is important to note that although p70S6K is 
well recognized as a downstream target of mTOR, phosphorylation of mTOR at Ser2448 is also 
considered to represent a feedback signal from p70S6K [50]. If indeed the case, then ATRA-
mediated p70S6K activation in mASCs may possibly be reliant on increases in mTOR activity 
through the phosphorylation of sites other than Ser2448. Certainly, mTOR has been reported to 
have several potential phosphorylation sites whose functions remain largely undefined [51]. As 
with rapamycin treatment, loss-of-function of HtrA1 also resulted in reductions in mTOR and 
p70S6K phosphorylation in the absence of any changes in phospho-Akt. However, in contrast to 
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rapamycin, the removal of HtrA1 was unable to completely abolish mTOR or p70S6K 
phosphorylation. 
 Although p70S6K activity is considered to be of paramount importance in determining 
mASC adipocyte lineage commitment [52], its functional role in mASC osteogenesis has not yet 
been established. Our findings from studies using the mTOR inhibitor rapamycin, along with 
siRNA-dependent inhibition of Rps6kb1 gene expression, confirmed that the mTOR/p70S6K 
signaling pathway was indeed an essential requirement for efficient mASC osteogenesis and 
mASC-derived osteoblast mineralization. As far as we are aware, this is the first report to 
demonstrate such a role for mTOR/p70S6K in ATRA-mediated mASC osteogenesis. Therefore, 
these studies identified both HtrA1 and mTOR/p70S6K as being important regulators of ATRA-
mediated mASC osteogenesis. However, it was still unclear as to whether HtrA1’s ability to 
regulate p70S6K phosphorylation in response to ATRA was directly related to its pro-osteogenic 
effects. We therefore performed a study in which we introduced plasmids encoding DNA for 
either constitutively active or kinase inactive mutants of p70S6K into HtrA1-deficient mASCs in 
an attempt to rescue osteoblastogenesis. Indeed, our results revealed that the mineralizing 
capacity of HtrA1-deficient mASC-derived osteoblasts could be fully restored when cells were 
engineered to express the constitutively active p70S6K mutant.  
These findings therefore identify p70S6K activation as a regulatory target of HtrA1 and 
an important event in mediating HtrA1’s pro-osteogenic effects in ATRA-stimulated mASCs. 
However, based on the fact that mTOR phosphorylation at Ser2448 may be the result of 
feedback regulation by p70S6K, further investigations are needed in order to determine whether 
HtrA1 can directly influence mTOR activation. Certainly, we would anticipate that if HtrA1 
were acting to regulate p70S6K activity through its interaction with TSC2 [16], then reductions 
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in mTOR activity would be apparent [53]. However, the suggestion that the TSC-complex may 
in fact regulate p70S6K independently of mTOR [54], may offer an additional means by which 
HtrA1 could activate p70S6K without the need for alterations in mTOR activity. Alternatively, 
HtrA1 may act to regulate p70S6K phosphorylation through mTOR, but in a TSC2-independent 
manner. Certainly, mTOR is not solely reliant on TSC2 inhibition for its activation as confirmed 
by studies in which Akt was shown to activate mTOR by relieving the inhibitory effects of 
proline-rich Akt/PKB substrate 40 kDa (PRAS40) on mTORC1 [55], and more recently, through 
its ability to promote mTORC1 phosphorylation at Ser1415 via the actions of IkB kinase alpha 
(IKKα) [56]. Further studies are therefore required in order to ascertain the involvement of TSC2 
and mTOR in mediating the effects of HtrA1 on p70S6K phosphorylation in osteogenic mASCs.  
Despite us having now demonstrated HtrA1 to be a positive regulator of both mASC and 
hBMSC [7] osteogenesis, its role in mediating bone formation remains highly controversial. This 
is highlighted by findings from previous studies in which HtrA1 was deemed to be a negative 
regulator of osteogenesis in stromal cells derived from long-term bone marrow cultures 
(LTBMCs) [31] and mouse 2T3 osteoblasts [57]. By contrast however, a more recent report has 
identified HtrA1 as being a necessary requirement for the osteogenic differentiation of 
periodontal ligament cells [58]. One possible explanation for such discrepancies may lie in the 
fact that in each of these studies, a different cell culture system was used. If indeed the case, this 
would imply that HtrA1 acts to mediate cell-specific responses to osteogenic stimuli, the result 
of which may impart an inhibitory or enhancing effect on osteogenic induction. Interestingly, our 
new findings also demonstrate that HtrA1’s involvement in regulating mASC osteogenesis 
extends beyond it’s ability to influence ATRA-mediated osteogenic induction as evidenced by 
significant reductions in mineral formation in HtrA1-deficient mASC cultures stimulated with 
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BMP-2. In order to try and further elucidate HtrA1’s role in regulating bone formation, 
investigations have also been conducted in mice with a targeted gene deletion of HtrA1 [30]. 
However, although HtrA1-deficient mice displayed significant increases in several bone 
parameters, the influence of such changes on bone quality and strength remain to be determined. 
Furthermore, no studies were undertaken to address the possible involvement of compensatory 
mechanisms in HtrA1 deficient mice, such as the upregulation of other members of the HtrA 
family (e.g. HtrA3 and HtrA4), which may also have an influence on bone formation. Clearly, 
more in-depth investigations are required in order to reconcile these conflicting studies and 
thereby help clarify HtrA1’s role as a modulator of bone formation. 
In summary, we have identified p70S6K as an important regulator of mASC 
osteogenesis, being activated in response to ATRA via pathways involving mTOR and HtrA1 
(Fig. 6). As such, it is proposed that HtrA1 represents a newly identified positive regulator of 
ATRA-mediated mASC osteogenesis and mASC-derived osteoblast mineralization.  
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FIG. 1. Effect of HtrA1 knockdown on osteogenic induction of mASCs. mASCs were pre-
treated with control siRNA (siControl) or 2 selected siRNAs targeting HtrA1 (siHtrA1-A and 
siHtrA1-B) for 24 h and induced to undergo osteogenesis for up to 10 days. (A) Western blot 
analysis of HtrA1 protein in FCS-free concentrated supernatants from siRNA-treated mASCs 
after 4 days of osteogenic induction using an antibody specific for HtrA1. Gels were stained with 
Coomassie Blue to confirm equal protein loading. (B) Alizarin red staining of siRNA-treated 
mASCs 10 days post osteogenic induction. (C) Extracted Alizarin red stain was quantified and 
normalized to cell number. * p < 0.001 as compared to siControl using one-way ANOVA. Gene 
expression levels of HtrA1 (D) and Alpl (E) were determined in osteogenic mASCs at selected 
time points using RT-qPCR and the fold change as compared to uninduced mASCs (day 0) 
determined using the 2
-∆∆CT
 method. (F) ALP enzymatic activity levels were measured in 
siRNA-treated mASCs over the course of 10 days of osteogenic differentiation using a 
colorimetric-based ALP activity assay. All values are expressed as mean ± S.D (triplicates). * p 
< 0.05, ** p < 0.001 as compared to uninduced mASCs at day 0; 
#
 p < 0.05, 
##
 p < 0.001 
comparison between siControl and siHtrA1 using one-way ANOVA.   
 
FIG. 2. Western blot analysis of kinase activity in mASCs in response to ATRA-mediated 
osteogenic induction. (A) mASCs were stimulated with osteogenic medium (OM) for up to 2 h 
and cell lysates analysed by immunoblotting at selected time points using antibodies specific for 
phosphorylated or non-phosphorylated Akt, mTOR, p70S6K and 4E-BP1. A mouse anti-tubulin 
antibody was used to confirm equal protein loading. The influence of osteogenic induction on 
mASC protein phosphorylation was compared to undifferentiated mASCs (time point 0 min). (B) 
mASCs were pre-treated with control siRNA (siControl) or siRNA targeting HtrA1 (siHtrA1) for 
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24 h and stimulated with osteogenic medium (OM) for 10 min. Untreated mASCs incubated in 
growth medium (GM) alone served as non-differentiated controls. Cell lysates were extracted 
and analysed by immunoblotting using antibodies specific for phosphorylated or non-
phosphorylated Akt, mTOR, p70S6K, ribosomal protein rpS6 or 4E-BP1. A mouse anti-tubulin 
antibody was used to confirm equal protein loading. Fold changes in phosphorylated protein 
levels versus non-phosphorylated protein levels are indicated. Results are representative of at 
least two separate experiments.  
 
FIG. 3. Effect of rapamycin on osteogenic induction of mASCs. (A) mASCs were incubated 
with growth medium (GM) or osteogenic medium (OM) for 10 min and cell lysates analysed by 
immunoblotting using antibodies specific for phosphorylated or non-phosphorylated Akt, 
mTOR, or p70S6K. In order to assess the effects of mTOR inhibition on protein activation, cells 
were also pre-treated for 2 h with 20 nM rapamycin (Rap) or vehicle (0.1% DMSO) prior to 
osteogenic induction. A mouse anti-tubulin antibody was used to confirm equal protein loading. 
Results are representative of at least two separate experiments. Fold changes in phosphorylated 
protein levels versus non-phosphorylated protein levels are indicated. (B) The influence of 
different concentrations of rapamycin on mASC-derived osteoblast mineralization was 
determined by Alizarin red staining at day 14. (C) Extracted Alizarin red stain was quantified 
and normalized to cell number and comparisons made between vehicle-treated and rapamycin-
treated osteogenic mASCs. All values are expressed as mean ± S.D (triplicates). * p < 0.001 as 
compared to mASCs treated without rapamycin using one-way ANOVA.   
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FIG. 4. Effect of Rps6kb1 knockdown on osteogenic induction of mASCs. mASCs were pre-
treated with control siRNA (siControl) or 2 selected siRNAs targeting Rps6kb1 (siRps6kb1-A 
and siRps6kb1-B) for 24 h and induced to undergo osteogenesis for up to 14 days. (A) Western 
blot analysis of p70S6K and phospho-S6 ribosomal proteinrpS6 (p-rpS6) in siRNA-treated 
mASCs using antibodies specific for p70S6K and p-rpS6 respectively. A mouse anti-tubulin 
antibody was us d to confirm equal protein loading. (B) Alizarin red staining of siRNA-treated 
mASCs 14 days post osteogenic induction. (C) Extracted Alizarin red stain was quantified and 
normalized to cell number. * p < 0.001 as compared to siControl using one-way ANOVA. (D-F) 
Gene expression levels of Rps6kb1 (D), Alpl (E) and Spp1 (F) were determined in osteogenic 
mASCs at selected time points using RT-qPCR and the fold change as compared to uninduced 
mASCs determined using the 2
-∆∆CT
 method. All values are expressed as mean ± S.D 
(triplicates). * p < 0.05, ** p < 0.01, *** p < 0.001 as compared to uninduced mASCs at day 0; 
#
 
p < 0.01, 
##
 p < 0.001 comparison between siControl and siRps6kb1 using one-way ANOVA.  
 
FIG. 5. Influence of p70S6K activity on siHtrA1-mediated suppression of mASC osteogenesis. 
(A) mASCs were transfected with empty plasmid, or plasmids encoding influenza hemagglutinin 
(HA)-tagged constitutively active (p70S6KCA) or kinase inactive (p70S6KKI) p70S6K mutants 
and immunoblotting performed after 24 h using an HA-probe antibody (HA-p70S6K) or anti-
phospho-rpS6 ribosomal protein antibody (p-rpS6). A mouse anti-GAPDH antibody was used to 
confirm equal protein loading. (B) The effect of plasmid DNA transfection on siRNA-mediated 
HtrA1 gene silencing in mASCs was determined after 24 h using RT-qPCR. (C) The influence of 
plasmid DNA transfection on mASC-derived osteoblast formation in in HtrA1-deficient mASCs 
was determined by Alizarin red staining at day 21 post osteogenic induction. (D) Extracted 
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Alizarin red stain was quantified and normalized to cell number. All values are expressed as 
mean ± S.D (triplicates). * p < 0.01, ** p < 0.001 as compared to siControl/ empty plasmid 
treated cells; ; 
#
 p < 0.01, 
##
 p < 0.001 comparisons between siHtrA1/p70S6KCA and 
siHtrA1/p70S6KKI or siHtrA1/p70S6KCA and siHtrA1/empty plasmid using one-way ANOVA.  
 
FIG. 6. Model of ATRA-induced mASC osteogenesis. Based on our findings, we propose that 
ATRA drives osteoblast commitment of mASCs through activation of p70S6K in a non-
canonical and non-genomic manner. This appears not only to be dependent on rapamycin-
sensitive signaling pathways, but also on the actions of HtrA1. However, further investigations 
are required in order to determine HtrA1’s mechanism of action and to clarify the potential 
involvement of the HtrA1 substrate TSC2 in mediating its effects on p70S6K activity and mASC 
osteogenesis. 
 
Supplementary Fig. S1. Effect of HtrA1 knockdown on BMP-2-dependent osteogenic induction 
of mASCs. mASCs were pre-treated with control siRNA (siControl) or an siRNA targeting 
HtrA1 (siHtrA1) for 24 h and induced to undergo osteogenesis for 21 days in the absence 
(untreated) or presence of BMP-2 (100 ng/ml). (A) Alizarin red staining of siRNA-treated 
mASCs 21 days post osteogenic induction. (B) Extracted Alizarin red stain was quantified and 
normalized to cell number. * p < 0.01 as compared to siControl using Student’s t-test.  
 
Supplementary Fig. S2. Effect of S6K1 inhibitor PF-4708671 on ATRA-induced osteogenic 
induction of mASCs. mASCs were induced to undergo osteogenic induction in the absence or 
presence of PF-4708671 at 10 or 20 µM for 15 days. (A) Alizarin red staining of PF-4708671-
Page 38 of 46
Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801
Stem Cells and Development
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only/Not for Distribution
treated mASCs 15 days post osteogenic induction. (B) Extracted Alizarin red stain was 
quantified and normalized to cell number. * p < 0.01 as compared to untreated mASCs using 
one-way ANOVA. 
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FIG. 1. Effect of HtrA1 knockdown on osteogenic induction of mASCs. mASCs were pre-treated with control 
siRNA (siControl) or 2 selected siRNAs targeting HtrA1 (siHtrA1-A and siHtrA1-B) for 24 h and induced to 
undergo osteogenesis for up to 10 days. (A) Western blot analysis of HtrA1 protein in FCS-free concentrated 
supernatants from siRNA-treated mASCs after 4 days of osteogenic induction using an antibody specific for 
HtrA1. Gels were stained with Coomassie Blue to confirm equal protein loading. (B) Alizarin red staining of 
siRNA-treated mASCs 10 days post osteogenic induction. (C) Extracted Alizarin red stain was quantified and 
normalized to cell number. * p < 0.001 as compared to siControl using one-way ANOVA. Gene expression 
levels of HtrA1 (D) and Alpl (E) were determined in osteogenic mASCs at selected time points using RT-
qPCR and the fold change as compared to uninduced mASCs (day 0) determined using the 2-∆∆CT method. 
(F) ALP enzymatic activity levels were measured in siRNA-treated mASCs over the course of 10 days of 
osteogenic differentiation using a colorimetric-based ALP activity assay. All values are expressed as mean ± 
S.D (triplicates). * p < 0.05, ** p < 0.001 as compared to uninduced mASCs at day 0; # p < 0.05, ## p < 
0.001 comparison between siControl and siHtrA1 using one-way ANOVA.    
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FIG. 2.  Western blot analysis of kinase activity in mASCs in response to ATRA-mediated osteogenic 
induction. (A) mASCs were stimulated with osteogenic medium (OM) for up to 2 h and cell lysates analysed 
by immunoblotting at selected time points using antibodies specific for phosphorylated or non-
phosphorylated Akt, mTOR, p70S6K and 4E-BP1. A mouse anti-tubulin antibody was used to confirm equal 
protein loading. The influence of osteogenic induction on mASC protein phosphorylation was compared to 
undifferentiated mASCs (time point 0 min). (B) mASCs were pre-treated with control siRNA (siControl) or 
siRNA targeting HtrA1 (siHtrA1) for 24 h and stimulated with osteogenic medium (OM) for 10 min. Untreated 
mASCs incubated in growth medium (GM) alone served as non-differentiated controls. Cell lysates were 
extracted and analysed by immunoblotting using antibodies specific for phosphorylated or non-
phosphorylated Akt, mTOR, p70S6K, rpS6 or 4E-BP1. A mouse anti-tubulin antibody was used to confirm 
equal protein loading. Fold changes in phosphorylated protein levels versus non-phosphorylated protein 
levels are indicated. Results are representative of at least two separate experiments.  
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FIG. 3.  Effect of rapamycin on osteogenic induction of mASCs. (A) mASCs were incubated with growth 
medium (GM) or osteogenic medium (OM) for 10 min and cell lysates analysed by immunoblotting using 
antibodies specific for phosphorylated or non-phosphorylated Akt, mTOR, or p70S6K. In order to assess the 
effects of mTOR inhibition on protein activation, cells were also pre-treated for 2 h with 20 nM rapamycin 
(Rap) or vehicle (0.1% DMSO) prior to osteogenic induction. A mouse anti-tubulin antibody was used to 
confirm equal protein loading. Results are representative of at least two separate experiments. Fold changes 
in phosphorylated protein levels versus non-phosphorylated protein levels are indicated. (B) The influence 
of different concentrations of rapamycin on mASC-derived osteoblast mineralization was determined by 
Alizarin red staining at day 14. (C) Extracted Alizarin red stain was quantified and normalized to cell number 
and comparisons made between vehicle-treated and rapamycin-treated osteogenic mASCs. All values are 
expressed as mean ± S.D (triplicates). * p < 0.001 as compared to mASCs treated without rapamycin using 
one-way ANOVA.    
53x28mm (600 x 600 DPI)  
 
 
Page 42 of 46
Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801
Stem Cells and Development
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only/Not for Distribution
  
 
 
FIG. 4.  Effect of Rps6kb1  knockdown on osteogenic induction of mASCs. mASCs were pre-treated with 
control siRNA (siControl) or 2 selected siRNAs targeting Rps6kb1  (siRps6kb1-A and siRps6kb1-B) for 24 h 
and induced to undergo osteogenesis for up to 14 days. (A) Western blot analysis of p70S6K and phospho-
rpS6 (p-rpS6) in siRNA-treated mASCs using antibodies specific for p70S6K and p-rpS6 respectively. A 
mouse anti-tubulin antibody was used to confirm equal protein loading. (B) Alizarin red staining of siRNA-
treated mASCs 14 days post osteogenic induction. (C) Extracted Alizarin red stain was quantified and 
normalized to cell number. * p < 0.001 as compared to siControl using one-way ANOVA. (D-F) Gene 
expression levels of Rps6kb1  (D), Alpl (E) and Spp1 (F) were determined in osteogenic mASCs at selected 
time points using RT-qPCR and the fold change as compared to uninduced mASCs determined using the 2-
∆∆CT method. All values are expressed as mean ± S.D (triplicates). * p < 0.05, ** p < 0.01, *** p < 0.001 
as compared to uninduced mASCs at day 0; # p < 0.01, ## p < 0.001 comparison between siControl and 
siRps6kb1 using one-way ANOVA.  
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FIG. 5.  Influence of p70S6K activity on siHtrA1-mediated suppression of mASC osteogenesis. (A) mASCs 
were transfected with empty plasmid, or plasmids encoding influenza hemagglutinin (HA)-tagged 
constitutively active (p70S6KCA) or kinase inactive (p70S6KKI) p70S6K mutants and immunoblotting 
performed after 24 h using an HA-probe antibody (HA-p70S6K) or anti-phospho-rpS6 antibody (p-rpS6). A 
mouse anti-GAPDH antibody was used to confirm equal protein loading. (B) The effect of plasmid DNA 
transfection on siRNA-mediated HtrA1 gene silencing in mASCs was determined after 24 h using RT-qPCR. 
(C) The influence of plasmid DNA transfection on mASC-derived osteoblast formation in HtrA1-deficient 
mASCs was determined by Alizarin red staining at day 21 post osteogenic induction. (D) Extracted Alizarin 
red stain was quantified and normalized to cell number. All values are expressed as mean ± S.D 
(triplicates). * p < 0.01, ** p < 0.001 as compared to siControl/ empty plasmid treated cells; ; # p < 0.01, 
## p < 0.001 comparisons between siHtrA1/p70S6KCA and siHtrA1/p70S6KKI or siHtrA1/p70S6KCA and 
siHtrA1/empty plasmid using one-way ANOVA.  
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FIG. 6. Model of ATRA-induced mASC osteogenesis. Based on our findings, we propose that ATRA drives 
osteoblast commitment of mASCs through activation of p70S6K in a non-canonical and non-genomic 
manner. This appears not only to be dependent on rapamycin-sensitive signaling pathways, but also on the 
actions of HtrA1. However, further investigations are required in order to determine HtrA1’s mechanism of 
action and to clarify the potential involvement of the HtrA1 substrate TSC2 in mediating its effects on 
p70S6K activity and mASC osteogenesis.  
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Supplementary FIG. S1. Effect of HtrA1 knockdown on BMP-2-dependent osteogenic induction of mASCs. 
mASCs were pre-treated with control siRNA (siControl) or an siRNA targeting HtrA1 (siHtrA1) for 24 h and 
induced to undergo osteogenesis for 21 days in the absence (untreated) or presence of BMP-2 (100 ng/ml). 
(A) Alizarin red staining of siRNA-treated mASCs 21 days post osteogenic induction. (B) Extracted Alizarin 
red stain was quantified and normalized to cell number. * p < 0.01 as compared to siControl using Student’s 
t-test.  
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Supplementary FIG. S2. Effect of S6K1 inhibitor PF-4708671 on ATRA-induced osteogenic induction of 
mASCs. mASCs were induced to undergo osteogenic induction in the absence or presence of PF-4708671 at 
10 or 20 µM for 15 days. (A) Alizarin red staining of PF-4708671-treated mASCs 15 days post osteogenic 
induction. (B) Extracted Alizarin red stain was quantified and normalized to cell number. * p < 0.01 as 
compared to untreated mASCs using one-way ANOVA.  
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